STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRD
  4. [Form 4] Opus Genetics, Inc. Insider Trading Activity

Opus Genetics (IRD) director awarded 67,000 RSUs in stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Opus Genetics, Inc. director Cam Gallagher reported a new equity award and his current share holdings. On January 6, 2026, he received a grant of 67,000 restricted stock units (RSUs) of common stock at a price of $0. These RSUs vest on December 29, 2026, if he continues to provide service through that date.

After this grant, Gallagher beneficially owns 1,991,430 shares of Opus Genetics common stock directly. The filing also notes 83,000 shares held indirectly by him as custodian for a minor child under the Uniform Transfers to Minors Act, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Gallagher Cam
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 67,000 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,991,430 shares (Direct); Common Stock — 83,000 shares (Indirect, By Garret Gallagher - Custodian UTMA/UGMA)
Footnotes (1)
  1. Represents a grant of restricted stock units which vest on December 29, 2026, subject to the Reporting Person's continuing service through the vesting date. These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gallagher Cam
(Last) (First) (Middle)
C/O OPUS GENETICS, INC.
8 DAVIS DRIVE, SUITE 220
(Street)
DURHAM NC 27713
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 A 67,000(1) A $0 1,991,430 D
Common Stock 83,000 I By Garret Gallagher - Custodian UTMA/UGMA(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a grant of restricted stock units which vest on December 29, 2026, subject to the Reporting Person's continuing service through the vesting date.
2. These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ Amy Rabourn, by Power of Attorney 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Opus Genetics (IRD) report for Cam Gallagher?

Cam Gallagher, a director of Opus Genetics, Inc., reported receiving a grant of 67,000 restricted stock units of common stock on January 6, 2026.

At what price were the 67,000 Opus Genetics RSUs granted to Cam Gallagher?

The 67,000 restricted stock units of Opus Genetics common stock were granted to Cam Gallagher at a price of $0 per unit.

When do Cam Gallagher’s Opus Genetics RSUs vest?

The 67,000 restricted stock units granted to Cam Gallagher vest on December 29, 2026, subject to his continuing service through that vesting date.

How many Opus Genetics shares does Cam Gallagher own after the reported transaction?

Following the reported grant, Cam Gallagher beneficially owns 1,991,430 shares of Opus Genetics common stock directly.

What are the 83,000 Opus Genetics shares held indirectly for Cam Gallagher?

The filing lists 83,000 shares of Opus Genetics common stock held indirectly by Cam Gallagher as custodian for a minor child under the Uniform Transfers to Minors Act. He disclaims beneficial ownership of these shares except for any pecuniary interest.

What is Cam Gallagher’s role at Opus Genetics (IRD)?

Cam Gallagher is reported as a director of Opus Genetics, Inc. and is not listed as an officer or 10% owner in this filing.